CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia October 13, 2024 Innovative study captures real-time data on balance loss in older adults October 4, 2024 Disparities in access to novel infusion treatment for Alzheimer’s disease revealed May 15, 2025